Dr. Alex Eapen
|
About meDr. Alex Eapen is a Principal Scientist in the R&D Scientific & Regulatory Affairs group at Cargill. Cargill is a privately-owned, multinational corporation with over 150,000 employees in 70 countries, working together across numerous business segments to nourish the world in a safe, responsible and sustainable way. Dr. Eapen has 15 years of experience in regulatory toxicology, with an emphasis on non-clinical safety testing of FDA-regulated products, including pharmaceuticals, industrial chemicals, medical devices, consumer products, human food and animal feed.
Dr. Eapen received his BS degree in biochemistry from the University of Dayton in 1995, conducting research on synthesis of DNA-binding conjugates with potential as oncology agents. Having developed an interest in furthering his education in the area of medicinal chemistry and oncology research, he pursued a PhD in Pharmacology from the University of Iowa. During his graduate training, Dr. Eapen conducted research in the areas of growth factor signal transduction and cell cycle regulation. He also served as a lecturer and course coordinator for several graduate-level courses in pharmacology. Dr. Eapen completed his PhD in 2001 and pursued additional research training opportunities as a post-doctoral fellow at the Mayo Clinic Division of Oncology Research. While at the Mayo Clinic, he conducted research in the area of cell cycle checkpoint regulation and radio-sensitizing agents for chemotherapy. Upon completion of the post-doctoral fellowship, Dr. Eapen took a position as a Staff Toxicologist at WIL Research Laboratories, LLC. During his 11 years at WIL Research, Dr. Eapen was involved in the design, conduct and interpretation of 100s of non-clinical toxicology tests to evaluate the safety of FDA-regulated products for numerous companies spanning the pharmaceutical, chemical and food industries. Prior to leaving WIL Research, Dr. Eapen held the position of Director of General Toxicology, being ultimately responsible for the business conduct and oversight of the general, acute, inhalation and infusion toxicology departments, with annual revenues exceeding 50 million dollars. Following his time at WIL Research, Dr. Eapen joined the Global Scientific and Regulatory Affairs Department at Cargill and has been a Principal Scientist within this group for over 3 years. In this role, Dr. Eapen is responsible for the safety and regulatory substantiation of novel food and feed ingredients as well as bio-industrial and personal care products. Dr. Eapen has been an active member of the Society of Toxicology as well as the American College of Toxicology since 2004 and has been a Diplomate of the American Board of Toxicology since 2005. Dr. Eapen has published over 20 papers in peer review publications and has presented at several national and international meetings. |
|
|
|
|